Because novel therapeutic approaches to glioma treatment are currently being developed, such as the targeted inhibition of IDH-mutants (52), it is anticipated that this method will be hugely beneficial for accurate in vivo assessment of tumor status and glioma progression at 3 T through robust 2-HG and Lac estimation. This evidence concerns the gene IDH2 and central nervous system cancer.